As to esophageal cancer, pyrotinib sensitized HER2-positive esophageal cancer cells to radiotherapy by inhibiting HER2 phosphorylation, inducing G0/G1 phase arrest, thus reducing EMT and DNA repair [69]. The gene discussed is ERBB2; the disease is esophageal cancer.